ArticleMedicine2026
Enhanced tumor control in non-small cell lung cancer using intensity-modulated radiotherapy combined with microwave hyperthermia: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the enhanced tumor control in patients with non-small cell lung cancer (NSCLC) using intensity-modulated radiotherapy (IMRT) combined with microwave hyperthermia (MWD). We retrospectively analyzed the clinical data of 134 patients with NSCLC admitted to our hospital from March 2021 to February 2024. Among them, 66 patients received IMRT alone (IMRT group) and 68 patients received IMRT combined with MWD (combined group). Tumor control rates, serum tumor markers, immune function, and toxic side effects were evaluated. The tumor control rate was significantly higher in the combined group (82.35%) than in the IMRT group (69.70%; P < .05). After treatment, the combined group showed significantly lower levels of carbohydrate antigen 125 (CA125), cytokeratin 19-fragments (Cyfra21-1), and carcinoembryonic antigen (CEA) compared to the IMRT group (P < .05). Furthermore, the levels of CD3+, CD4+, and CD4+/CD8+ ratios in the combined group were significantly higher than those in the IMRT group (P < .05). No significant difference in toxic side effects was observed between the 2 groups (P > .05). IMRT combined with MWD for NSCLC can effectively downregulate tumor markers, restore immune function, and improve tumor control rates without increasing toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.